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Background and aims: Monoglyceride lipase (MGL) catalyzes the ﬁnal step of lipolysis by degrading
monoglyceride (MG) to glycerol and fatty acid. MGL also hydrolyzes and thereby deactivates 2-
arachidonoyl glycerol (2-AG), the most abundant endocannabinoid in the mammalian system. 2-AG
acts as full agonist on cannabinoid receptor type 1 (CB1R) and CB2R, which are mainly expressed in
brain and immune cells, respectively. Thus, we speculated that in the absence of MGL, increased 2-AG
concentrations mediate CB2R signaling in immune cells to modulate inﬂammatory responses, thereby
affecting the development of atherosclerosis.
Methods and results: We generated apolipoprotein E (ApoE)/MGL double-knockout (DKO) mice and
challenged them with Western-type diet for 9 weeks. Despite systemically increased 2-AG concentra-
tions in DKO mice, CB2R-mediated signaling remains fully functional, arguing against CB2R desensiti-
zation. We found increased plaque formation in both en face aortae (1.3-fold, p ¼ 0.028) and aortic valve
sections (1.5-fold, p ¼ 0.0010) in DKO mice. Interestingly, DKO mice also presented reduced lipid (12%,
p ¼ 0.031) and macrophage content (18%, p ¼ 0.061), elevated intraplaque smooth muscle staining (1.4-
fold, p ¼ 0.016) and thicker ﬁbrous caps (1.8-fold, p ¼ 0.0032), together with a higher ratio of collagen to
necrotic core area (2.5-fold, p ¼ 0.0003) and expanded collagen content (1.6-fold, p ¼ 0.0007), which
suggest formation of less vulnerable atherosclerotic plaques. Treatment with a CB2R inverse agonist
prevents these effects in DKO mice, demonstrating that the observed plaque phenotype in DKO mice
originates from CB2R activation.
Conclusion: Loss of MGL modulates endocannabinoid signaling in CB2R-expressing cells, which
concomitantly affects the pathogenesis of atherosclerosis. We conclude that despite larger lesion size loss
of MGL improves atherosclerotic plaque stability. Thus, pharmacological MGL inhibition may be a novel
intervention to reduce plaque rupture.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
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Intracellular lipolysis requires three consecutive steps, mediated
by adipose triglyceride lipase, hormone-sensitive lipase, and
monoglyceride lipase (MGL) [1]. Thus, MGL catalyzes the ﬁnal step
in triglyceride (TG) hydrolysis by cleaving monoglyceride (MG) to
glycerol and fatty acid. In addition to MGL, at least four otherarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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[2], fatty acid amide hydrolase [3], and a/b hydrolase domain-
containing 6 and 12 [4].
Among the MG substrates hydrolyzed by MGL is 2-
arachidonoyl glycerol (2-AG), the most abundant endocannabi-
noid (EC) in mammals. 2-AG acts as full agonist on cannabinoid
receptor type 1 (CB1R) [5] and CB2R [6] and several of its effects
are mimicked by D9-tetrahydrocannabinol (THC), the psychoac-
tive component of Cannabis sativa. CB1R is predominantly
expressed in brain, whereas lower receptor densities are found in
liver, pancreas, adipose tissue, and skeletal muscle. Its activation
is associated with increased food intake [7], lipogenesis, non-
adipose tissue steatosis [8], insulin resistance [9], and thrombo-
genesis. CB1R inhibition results in reduced oxidative stress and
improved endothelial function [10] as well as reduced athero-
sclerosis in LDL receptor-deﬁcient (/) mice [11]. Thus, CB1R
activation promotes the development of the metabolic syndrome
and concomitantly atherosclerosis development. In contrast,
CB2R is highly expressed in immune cells and the signaling
mediated by this receptor leads to impaired antigen presentation
[12,13], lymphocyte and macrophage migration [14,15], modula-
tion of cytokine and chemokine production (reviewed in [16]),
and induction of apoptosis [17,18]. These effects diminish critical
functions of the immune system and therefore presumably
attenuate atherosclerosis-associated inﬂammatory responses.
Indeed, CB2R blockade was shown to aggravate atherogenesis
[19,20] and CB2R activation to attenuate pro-inﬂammatory re-
sponses [21] and atherosclerosis development [15,20,21]. Low
doses of THC reduced atherosclerotic lesion size in apolipopro-
tein E (ApoE)/ mice by decreasing macrophage migratory
capacity, which resulted in reduced lesional macrophage content
[15]. These beneﬁcial effects were abolished when mice were
treated with a speciﬁc CB2R antagonist, suggesting that CB2R but
not CB1R signaling is crucial for the anti-atherosclerotic effect of
THC [15]. In contrast, increased 2-AG production in plaques of
ApoE/ mice together with elevated in vitro chemotaxis of
macrophages toward 2-AG argue against an atheroprotective role
of 2-AG in atherosclerosis [22]. Thus, a clear picture of the in vivo
effects of 2-AG on atherosclerotic plaque formation is still
missing.
Although MGL was discovered simultaneously with hormone-
sensitive lipase in 1964 [23], MGL/ mice have been generated
only recently [24e26]. MGL deﬁciency in mice impairs lipolysis and
attenuates diet-induced insulin resistance [26]. Defective degra-
dation of 2-AG, however, does not provoke cannabinomimetic ef-
fects on feeding behavior, lipogenesis, and energy expenditure due
to downregulation and blunting of CB1R-mediated signaling
(desensitization) [24e26].
MGL directly affects lipolysis and indirectly inﬂuences energy
metabolism, lipid homeostasis, and immune responses by
degrading 2-AG and modulating the EC system. We therefore hy-
pothesized that in the absence of MGL, increased 2-AG concentra-
tions may act on CB2R, thereby modulating immune responses and
atherogenesis. Despite increased atherosclerotic lesion formation
in ApoE/MGL double-knockout (DKO) compared to ApoE/mice,
plaques from DKO mice have reduced lipid and macrophage con-
tent, markedly increased amount of collagen, and a thicker ﬁbrous
cap, demonstrating lesion stabilization. These effects in DKO mice
were reversed by in vivo CB2R antagonism, indicating that the
atherosclerotic phenotype of DKO mice is mediated via CB2R
activation.
2. Materials and methods
Full details are presented in the Online Supplement materials.2.1. Animals and diets
ApoE/MGL/ (DKO) mice were generated by crossing
ApoE/ (The Jackson Laboratory, Bar Harbor, ME) with MGL/
mice [26]. At the age of 6e8 weeks, female mice were challenged
with Western-type diet (WTD, 21% fat, 0.2% cholesterol; Ssniff
Spezialdiaeten GmbH, Soest, Germany) for 9 weeks to induce
atherosclerotic plaque formation. Where indicated, mice were
treated daily with the CB2R inverse agonist SR144528 (Cayman
Chemical, Ann Arbor, MI) during the last three weeks of WTD
feeding by gastric gavage. All protocols were approved by the
Austrian Federal Ministry of Science, Research and Economy,
Vienna, Austria.
2.2. Quantiﬁcation of 2-AG in plasma, aorta, and macrophages
Two hundred ml plasma were mixed with 800 ml dH2O. Aortae
were homogenized in 800 ml dH2O. Eight hundred ml of macrophage
lysate was used for the extraction. Lipids were extracted twice with
4 ml CHCl3:MeOH:H2O (2:1:0.6, v:v:v) containing 2 mg C17:0 MG
(Avanti Lipids, Alabaster, AL) as internal standard. MGs were iso-
lated by solid phase extraction using a self-packed silica gel column.
Fractions were obtained by eluting lipids with 99:1 and 90:10
CHCl3:MeOH (v:v) consecutively. 2-AG concentrations were quan-
titated in the latter fraction using an AQUITY-UPLC (Waters, Man-
chester, UK) equipped with a BEH-C18-column (2.1  150 mm,
1.7 mm; Waters), coupled to a SYNAPT™ G1 qTOF HD mass spec-
trometer (Waters) equipped with an ESI source [27].
2.3. Complete blood cell count and immunophenotyping of bone
marrow
Complete blood cell count was performed with the Cell Counter
Analyzer MS9-5V (Melet Schloesing Laboratories GmbH, Maria
Enzersdorf, Austria).
Washed cell pellets from bone marrow were resuspended in
200 ml antibody cocktail and incubated at RT for 10 min, washed in
buffer, and subsequently analyzed by ﬂow cytometry.
2.4. White blood cell (WBC) half-life
Mice were injected with 3 mg EZ-Link Sulfo-NHS-Biotin (Pierce
Biotechnology, Rockford, IL) into the tail vein. At indicated time
points, blood was drawn from vena facialis. Red blood cells were
lysed with ammoniumechlorideepotassium lysis buffer. Remain-
ing WBCs were washed with PBS/EDTA (400  g, 5 min, 4 C). Cells
were ﬁxed with 10% neutral buffered formalin (methanol-free) for
10 min at 4 C, washed once with PBS/EDTA, and stained with
Streptavidin-PE antibody (eBioscience, San Diego, CA) in PBS con-
taining 3% FCS (20 min, 4 C). Data were acquired on a FACSCalibur
(BD Biosciences, San Jose, CA) and the analysis was performed using
Flowjo (Treestar Inc, San Carlos, CA). The frequencies of speciﬁc cell
types were calculated as the percentage of living cells.
2.5. MG hydrolase activity assay
MG hydrolase activity was determined as described [26].
2.6. Cytosolic Ca2þ imaging using Fura-2/AM
Ca2þ imaging was performed as described [28].
2.7. In vivo macrophage phagocytosis assay
Mice were i.p. injected with 200 ml ﬂuorescein-labeled
Fig. 1. Increased plasma 2-AG concentrations in DKO mice. (A) Body weight
(n ¼ 14e15) and (B) food consumption of ApoE/ and DKO mice (n ¼ 5e7) during
WTD feeding. Data represent means ± SD. (C) Plasma 2-AG concentrations after 9
weeks of WTD feeding. Data represent means (n ¼ 5) þ SD. n.d. not detectable.
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Carlsbad, CA) suspended in HBSS. In vivo phagocytosis after 2 h of
injection was determined as previously described [29].
2.8. Preparation of histological sections and atheroassays
Anesthetizedmicewere perfusedwith PBS/EDTA for 10e15min.
The abdominal part of the aorta was removed and frozen in liquid
N2 for RNA isolation. Animals were perfused with 10% neutral
buffered formalin (methanol-free) for 15 min. The upper part of the
aorta was excised from the thoracic cavity and stored in formalin
until staining. Upper two thirds of the heart were ﬁxed with
formalin for 24 h and stored in 30% sucrose. One day before
sectioning, hearts were transferred into Neg-50™ frozen section
medium (Richard-Allan Scientiﬁc, Kalamazoo, MI). Serial sections
(7e8 mm) of aortic root were cut at 20 C using a cryostat-
microtome (HM 560 Cryo-Star; Microm International GmbH,
Walldorf, Germany).
Mean lesion area (mm2) was calculated from 14 to 15 consec-
utive Oil red O-stained sections per mouse. Sections were stained
immunohistochemically for the presence of macrophages, collagen,
smooth muscle cells, caspase 3, and CD31. For en face analysis,
aortae were dissected and plaques were stained with Oil red O as
described [30].
2.9. Statistics
Statistical analyses were performed using GraphPad Prism 5.0
software. Statistically signiﬁcant differences were determined by
Student's unpaired t-test and Welch correction (in case of unequal
variances) for two group comparison and ANOVA followed by
Bonferroni correction for multiple group comparison. Data repre-
sent mean values ± SD. Values of p < 0.05 were considered
signiﬁcantly different.
3. Results
3.1. DKO mice exhibit increased plasma 2-AG concentrations
Challenging of ApoE/ and DKO mice with WTD for 9 weeks
resulted in comparable body weight gain (Fig. 1A) and food intake
(ApoE/: 2.48 ± 0.37 g vs DKO: 2.75 ± 0.43 g, Fig. 1B). After 12 h of
fasting, plasma TG, total cholesterol (TC), free cholesterol (FC), and
cholesterol ester (CE) concentrations were comparable in both
genotypes either fed standard chow or Western-type diet (WTD)
(Table 1). Fast protein liquid chromatography revealed identical
fasting plasma lipoprotein proﬁles for TG (Supplementary Fig. S1A)
and TC concentrations (Supplementary Fig. S1B) between ApoE/
and DKO mice after WTD feeding. In plasma of DKO animals, we
measured 0.3 nmol/ml 2-AG (Fig. 1C), whereas in ApoE/ mice
plasma 2-AG concentrations were below the detection limit.
Interleukin 6 (IL-6) plasma levels were at comparable and low
levels in both genotypes, whereas monocyte chemoattractant
protein 1 (MCP-1) concentrations were reduced in DKO mice
(Supplementary Fig. S1C). These data indicate that MGL deﬁciency
on the ApoE/ background results in systemic accumulation of 2-
AG.
3.2. Increased number of circulating white blood cells (WBCs) in
DKO mice
Since EC signaling can inﬂuence immune responses and leuko-
cyte function, we determined WBC counts in ApoE/ and DKO
mice after 9 weeks of WTD feeding. The total number of WBCs was
increased in DKO mice (ApoE/: 7.91 ± 1.07  103 vs DKO:10.0 ± 1.10  103 cells/ml, p ¼ 0.0016) due to higher levels of lym-
phocytes, monocytes, and basophils, whereas the numbers of
neutrophils and eosinophils were unaltered (Fig. 2A). An increased
relative abundance of hematopoietic LinSca-1þc-Kitþ (LSK) cells
in the bone marrow of DKO mice (ApoE/: 0.17 ± 0.03 vs DKO:
0.26 ± 0.08%, p ¼ 0.039, Fig. 2B) and prolonged WBC half-life
(Fig. 2C) were contributing factors to elevated circulating WBC
numbers in DKO animals.3.3. EC signaling is intact in DKO macrophages
Macrophages originate from monocytes and represent the most
dominant cell type in the atheroma. Thus, we explored conse-
quences of MGL deﬁciency in these cells. We found comparable
expression levels of lipases, enzymes capable to degrade MGs and
generate 2-AG, and Cb2r (Fig. 3A). Cb1r transcript was absent in
macrophages from both genotypes. MG hydrolase activity was
markedly reduced in DKO (0.28 ± 0.01 mmol/mg*h) compared to
ApoE/ macrophages (0.50 ± 0.04, p ¼ 0.0016) (Fig. 3B).
Accordingly, macrophage 2-AG concentrations were signiﬁcantly
increased in DKO (63.19 ± 22.96 pmol/mg protein) compared to
ApoE/ cells (36.19 ± 7.10, p¼ 0.040) (Fig 3C), indicating thatMGL
is the key enzyme in macrophage 2-AG homeostasis. Unchanged
protein expression of CB2R (Fig. 3D), comparable cytosolic Ca2þ
responses to 2-AG treatment and an only slightly lower relative
response of DKO cells to the maximal, ATP-provoked Ca2þ ﬂux
(Fig. 3EeG) indicate that although DKO macrophages are unable to
clear 2-AG as efﬁciently as ApoE/ cells, their EC system remains
responsive to 2-AG rendering CB2R desensitization unlikely to
occur. This ﬁnding contrasts CB1R desensitization in brain of
MGL/ mice [24,25].3.4. Reduced foam cell formation in DKO macrophages
The formation of macrophage-derived foam cells is a hallmark
in atherogenesis. Therefore, we determined lipid parameters and
observed unaltered TG and CE (Fig. 4A) but reduced TC (ApoE:
Table 1
Plasma parameters of 12 h-fasted ApoE/ and DKO mice before and after WTD feeding for 8 weeks. Data represent mean (n ¼ 13e14) ± SD.
Chow diet Western-type diet (WTD)
ApoE/ DKO ApoE/ DKO
Triglyceride (mg/dl) 91.2 ± 15.5 92.6 ± 24.6 74.1 ± 15.3 76.5 ± 15.1
Total cholesterol (mg/dl) 224 ± 50.0 249 ± 40.9 1075 ± 167 1160 ± 173
Free cholesterol (mg/dl) 82.6 ± 20.1 91.6 ± 18.5 349 ± 26.9 356 ± 61.4
Cholesteryl ester (mg/dl) 141 ± 33.6 157 ± 26.9 726 ± 156 812 ± 134
Fig. 2. Increased circulating white blood cell (WBC) counts are associated with enhanced production and survival in DKO mice. (A) Absolute WBCs as means (n ¼ 8e9) þ SD. (B)
Bone marrow analysis by ﬂow cytometry: LSK populations (LinSca-1þc-Kitþ), myeloid progenitor LK cells (LinSca-1c-Kitþ), granulocyte/monocyte progenitors (GMP; Linc-
KitþCD34þFcgRII/IIIþ), monocyte/dendritic cell progenitors (MDP; Linc-Kitþ/IntCD115þFlt3þ), common lymphoid progenitors (CLP; Linc-KitloSca-1loIL7Raþ). Data represent means
(n ¼ 6e7) þ SD. (C) Half life of WBCs as means (n ¼ 7) ± SD. *, p < 0.05; **, p  0.01; ***, p  0.001.
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and FC (ApoE: 38.3 ± 6.77 vs DKO: 32.0 ± 2.77 mg/mg protein,
p ¼ 0.0465, Fig. 4C) concentrations under non-loaded conditions.
Upon loading with very low-density lipoprotein (VLDL) and acet-
ylated (ac)LDL, macrophages from DKO mice displayed signiﬁcant
reductions in TG (ApoE/ þ VLDL: 122 ± 9.36 vs DKO þ VLDL:
93.7 ± 15.6 mg/mg protein, p ¼ 0.005; ApoE/ þ acLDL:
25.3 ± 2.93 vs DKO þ acLDL: 17.2 ± 5.09 mg/mg protein, p ¼ 0.01;
Fig. 4A) and cholesterol concentrations (Fig. 4BeD). Nile red
staining of lipid droplets conﬁrmed our observation of reduced
foam cell formation upon lipoprotein loading of DKO macrophages
(Fig. 4E). mRNA expression of Cd36 (involved in fatty acid and li-
poprotein uptake) was reduced by 32% (p ¼ 0.0005). mRNA levels
of Msr1 (also known as scavenger receptor A), Sr-B1 (bidirectional
cholesterol transporter), and the ABC transporters Abca1 and Abcg1
(responsible for cholesterol efﬂux from the cells) were unaltered
(Fig. 4F). In accordance, cholesterol efﬂux toward HDL3 and ApoA-I
as acceptors was unchanged (Fig. 4G). Co-incubation of macro-
phages with acLDL and the CB2R inverse agonist SR144528 partiallyreverses the observed foam cell formation in DKO cells, suggesting
that this effect is at least in part mediated by CB2R signaling
(Fig. S2A, B). Comparable apoptosis and necrosis (Supplementary
Fig. S2CeE), mRNA expression levels of M1/M2 polarization
markers (Supplementary Fig. S2F), adhesion molecule ligands,
matrix metalloproteinase inhibitors (Supplementary Fig. S2G), and
in vivo phagocytic activity of ﬂuorescently labeled E. coli particles
(Supplementary Fig. S2H) argue against profound changes in
macrophage phenotype and function caused by alterations in 2-AG
concentrations in the circulation. Interestingly, when loaded with
acLDL, DKO macrophages have reduced mRNA expression of pro-
inﬂammatory IL-6 and increased expression of anti-inﬂammatory
IL-10 (Fig. 4H) compared to ApoE/ cells, indicating a polariza-
tion toward M2-like macrophages.
3.5. Alterations in the aortic EC signaling in DKO mice
In the aortae, 2-AG concentrations were 3.5-fold increased in
DKO compared to ApoE/mice (p < 0.0001; Fig. 5A). Quantitative
Fig. 3. EC signaling is intact in DKO macrophages. (A) Macrophage mRNA expression was analyzed in duplicate by real-time PCR and normalized to Hprt expression as reference
gene. Data represent means (n ¼ 4e5) þ SD. (B) MG hydrolase activity presented as means (n ¼ 6) þ SD. (C) Macrophage 2-AG concentrations presented as means (n ¼ 6) þ SD. (D)
Western blot analysis of CB2R protein expression in macrophages. Densitometric quantiﬁcation of CB2R/b-actin (loading control) represent means (n ¼ 3) þ SD. (E) Representative
traces of cytosolic Ca2þ signals in macrophages upon stimulation with 20 mM 2-AG and 200 mM ATP shown as normalized ratio (F380/F340)/R0. (F) Statistical evaluation of Ca2þ signals
in macrophages in response to 2-AG; (n ¼ 4e6) þ SD. (G) Cytosolic Ca2þ response of macrophages to 2-AG calculated as percentage of response to ATP; (n ¼ 4e6) þ SD. *, p < 0.05;
**, p  0.01; ***, p  0.001.
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(p ¼ 0.015) and Cb2r by 56% (p ¼ 0.0259) in abdominal aortae of
DKO compared to ApoE/ mice after 9 weeks of WTD feeding.
Expression levels of adhesion molecules such as P-selectin, E-
selectin, L-selectin, vascular cell adhesion molecule-1, and intra-
cellular adhesion molecule-1 (Fig. 5B) as well as matrix metal-
loproteinase (Mmp)-2 and Mmp-9 were comparable between both
genotypes. However, transcript levels of (Timp)-1 and Timp-2 were
signiﬁcantly increased by 5.1-fold (p ¼ 0.022) and 1.3-fold
(p ¼ 0.011), respectively, in DKO aortae compared to ApoE/
aortae (Fig. 5B), indicating increased inhibition of gelatinolytic
enzymes in the aortic tissue of DKOmice. Of note, mRNA expressionlevels of Mcp-1 and IL-1bwere increased, whereasMcp-5, Tnf-a, IL-
6, and Cox-2 remained at comparable expression levels between
DKO and ApoE/ aortae (Fig. 5C).
3.6. Enhanced lesion size with increased plaque stability in DKO
mice
Interestingly, we found increased plaque size in en face aortae of
DKO compared to ApoE/ mice (Fig. 5D) in total thoracic aorta
(ApoE/: 9.44 ± 3.71 vs DKO: 12.7 ± 3.87%, p¼ 0.028, Fig. 5E) and
arch area (ApoE/: 18.1 ± 7.56 vs DKO: 24.6 ± 6.70%, p ¼ 0.022,
Fig. 5F). The increase in plaque burden was even more pronounced
Fig. 4. Reduced foam cell formation in DKO macrophages. Peritoneal macrophages were plated in 6-well plates for 24 h ± VLDL or acetylated (ac)LDL (100 mg protein/ml medium).
After lipid extraction, (A) TG, (B) TC, and (C) FC concentrations were measured spectrophotometrically, and (D) CE concentrations were calculated as TC minus FC. Data represent
means (n ¼ 5e7) þ SD. (E) Lipid droplets were visualized after Nile red staining (2.5 mg/ml) by confocal laser scanning microscopy. (F) mRNA expression of lipid transport genes
analyzed in duplicate by real-time PCR and normalized to Hprt expression as reference gene. Data represent means (n ¼ 4e5) þ SD. Relative mRNA expression and associated
statistical parameters were determined by the 2DDCT method. (G) Cholesterol efﬂux to Apo-AI and HDL3 expressed as the percentage of [3H]cholesterol transferred from cells to the
medium. Data showmeans (n ¼ 3) ± SD of triplicate repeats. (H) mRNA expression of cytokines in macrophages treated with acLDL (100 mg protein/ml medium) for 24 h analyzed in
duplicate by real-time PCR and normalized to Hprt expression as reference gene. Data represent means (n ¼ 3e5) þ SD. *, p < 0.05; **, p  0.01; ***, p  0.001.
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DKO: 0.345 ± 0.09 mm2, p ¼ 0.001, Fig. 6A). However, the relative
abundance of neutral lipids within the lesions was reduced in DKO
plaques, as visualized by diminished Oil red O staining (ApoE/:
75.4 ± 12.5 vs DKO: 66.7 ± 7.95%, p ¼ 0.031, Fig. 6B). Since
macrophage-derived foam cells are the major component oflesional lipid accumulation, we performed MoMa-2 immuno-
staining, which revealed a trend to 19% reduced amount of mac-
rophages in DKO lesions (p ¼ 0.061; Fig. 6C). This ﬁnding
phenocopies our in vitro data with reduced foam cell formation in
DKO macrophages (Fig. 4A,B), indicating that another plaque
component strongly contributes to the increase in plaque size and
Fig. 5. Increased 2-AG concentrations and plaque size in aortae of DKO mice. (A) Aortic 2-AG concentrations after 9 weeks of WTD feeding presented as means (n ¼ 5) þ SD. (B, C)
mRNA expression analyzed in duplicate by real-time PCR and normalized to cyclophilin A expression as reference gene. Expression proﬁles and associated statistical parameters
were determined by the 2DDCT method. Data represent means (n ¼ 6e8) þ SD. (D) Oil red O (ORO) staining of en face aortae. Quantiﬁcation of lesion sizes in (E) total thoracic aortae
and (F) arch area. Bars represent means of 14e15 mice per group. *, p < 0.05; ***, p  0.001.
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(measured by Masson's Trichrome staining) was 1.6-fold increased
in DKO plaques (p ¼ 0.0007), comprising almost 40% of the total
lesion area (Fig. 6D). Concomitantly ﬁbrous caps were 1.8-fold
thicker (p ¼ 0.0032) in DKO plaques (Fig. 6E) This elevated
amount of collagen was likely caused by the increased abundance
of smooth muscle cells within the plaque (ApoE/: 2.91 ± 1.15 vs
DKO: 4.20 ± 1.49%, p ¼ 0.0155; Fig. 6F and Supplementary Fig. S3).
Gelatinolytic activities of conditioned media from cultivated peri-
toneal neutrophils, the most important cell type responsible for
plaque destabilization, showed comparable activities of pro-MMP-
9, MMP-9, pro-MMP-2, and MMP-2 (Supplementary Fig. S4).
Relative abundance of active caspase-3 was comparable between
both genotypes (p ¼ 0.742) (Fig. 6G and Supplementary Fig. S5).
Neovessel formation determined by anti-CD31 immunohisto-
chemistry (Fig. 6H) was absent in the plaques of both genotypes.
Interestingly, necrotic core size was reduced in DKO (13.7 ± 9.73%)
compared to ApoE/ mice (18.7 ± 6.41, p ¼ 0.052) (Fig. 6H). Of
note, the ratio of collagen to necrotic core, an important indicator of
plaque stability [31], was 2.5-fold increased (p ¼ 0.0003) (Fig. 6J),whereas the ratio of necrotic core to smooth muscle cells as an
indicator of plaque vulnerability was reduced by 53% in DKO ani-
mals (p ¼ 0.0025) (Fig. 6K). These results suggest that although
DKO mice exhibit larger lesions, their atheroma composition
(Fig. 6L) is favorably changed to a more stable plaque phenotype.
3.7. Plaque phenotype in DKO mice is reversed upon SR144528
treatment
To determine the role of CB2R activation in DKOmice in vivo, we
treated ApoE/ and DKO mice with the CB2R inverse agonist
SR144528 during the last three weeks of 8 week WTD feeding. We
found no difference in peripheral blood cell counts between DKO
and ApoE/ mice (Fig. 7A), indicating that CB2R activation me-
diates leukocytosis in DKO mice during WTD feeding. In addition,
we found comparable plaque size between ApoE/ and DKOmice
upon chronic CB2R blockade (ApoE/: 0.285 ± 0.072 vs DKO:
0.300 ± 0.046 mm2, p ¼ 0.68, Fig. 7B). Moreover, all beneﬁcial
changes in plaque structure were completely absent in DKO
compared to control mice upon SR144528 treatment, as evidenced
Fig. 6. Atherosclerotic plaques are more stable in DKO mice. (A) Total lesion size measurements, (B) Oil red O (ORO)-stained lipids (magniﬁcation: 5), (C) MoMa-2 immuno-
histochemically-stained macrophages (red) (magniﬁcation: 5), (D) Masson's Trichrome-stained collagen (blue) (magniﬁcation: 5), (E) ﬁbrotic cap thickness (n ¼ 14e15)
(magniﬁcation: 20), (F) a-smooth muscle actin (a-SMA) immunohistochemically-stained smooth muscle cells (red) (magniﬁcation: 15), (G) active caspase-3 immunohis-
tochemically-stained apoptotic cells (red) (magniﬁcation: 15), and (H) CD31 immunohistochemically-stained neovessels (brown) (magniﬁcation: 15). Data represent mean
values of 15 aortic valve sections for lesion size measurements and 3 aortic valve sections in the area of maximal plaque size for ORO, MoMa-2, Trichrome, a-SMA, active caspase-3,
and CD31 for each mouse. Bars represent means. Quantiﬁcation of (I) necrotic core per plaque area, (J) collagen per necrotic area (n ¼ 14e15), and (K) necrotic per a-SMA area
(n ¼ 14e15). Data represent means þ SD. (L) Distribution of necrotic core, macrophages, smooth muscle cells, and collagen within the plaque. Data represent means
(n ¼ 14e15) þ SD. *, p < 0.05; **, p  0.01; ***, p  0.001.
Fig. 6. (continued).
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(ApoE/: 57.8 ± 3.0 vs DKO: 61.8 ± 7.5%, p ¼ 0.25, Fig. 7C), mac-
rophages (ApoE/: 32.4 ± 9.3 vs DKO: 35.7 ± 3.6%, p ¼ 0.44,
Fig. 7D), collagen (ApoE/: 25.4 ± 6.3 vs DKO: 24.4 ± 6.2%,
p ¼ 0.80, Fig. 7E), and necrotic core (ApoE/: 15.8 ± 5.4 vs DKO:
15.3 ± 7.6%, p ¼ 0.92, Fig. 7F). These results unequivocally conﬁrm
that the observed phenotype in DKO mice originates from CB2R
activation.
4. Discussion
MGL is the rate-limiting enzyme for the breakdown of MG and,
speciﬁcally, of the EC 2-AG in multiple tissues including the brain.
Thus, MGL plays a central role in lipid and energy metabolism as
well as 2-AG turnover and signaling [26]. Due to multiple effects of
EC signaling on energy homeostasis and immune response, wespeculated that the lack of MGL may also affect the pathogenesis of
atherosclerosis. To investigate the consequences of MGL deﬁciency
on atherosclerosis development, we generated MGL/ mice on
the atherosclerotic ApoE/ background and challenged them
with WTD.
We found systemically increased 2-AG concentrations in the
DKO mice, indicating that MGL is capable to efﬁciently regulate 2-
AG homeostasis. However, expected cannabimimetic effects
mediated by CB1R such as increased food intake and body adiposity
were absent in DKO animals. These results phenocopy the state of
MGL/mice, inwhich increased brain 2-AG levels do not promote
CB1R-mediated signaling due to receptor desensitization via re-
ceptor downregulation and blunting of cannabimimetic signaling
[24e26]. As expected in the CB1R-desensitized model, plasma lipid
proﬁles remained unaltered between the genotypes, suggesting
that lipid homeostasis is unaffected.
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elevation. Chanda et al. stated that CB2R densities remain unaltered
in spleen of MGL/ mice [24], but to date no functional assay
addressed the inﬂuence of systemically increased 2-AG levels on
CB2R-expressing cells. mRNA expression of other lipases capable to
degrade MGs and enzymes responsible for 2-AG generation
remained unchanged in the absence of MGL. Our results indicate
that MGL represents the key enzyme responsible for MG hydrolysis
and 2-AG deactivation in macrophages, since MG hydrolase activity
was reduced by 44% and cellular 2-AG content was increased 75% in
DKO macrophages compared to the control cells. To assess a
possible CB2R desensitization, we performed a functional mea-
surement of CB2R activation in macrophages by stimulating cells
with 2-AG and measuring cytosolic Ca2þ levels. Unchanged cellular
Ca2þ response to 2-AG treatment indicates that DKO macrophages
retain their full functionality of CB2R and its signaling cascade with
no evidence of receptor desensitization. Although DKO mice have
systemically elevated 2-AG levels, CB2R-mediated signaling re-
mains fully functional. Thus, increased 2-AG concentrations can
potentiate cannabimimetic effects on CB2R-expressing immune
cells. As previously proposed, CB1R may be more prone to the
process of desensitization [32].
Elevated leukocyte numbers in the DKO mice indicate that MGL
deﬁciency affects immune functions and hematopoiesis in vivo,
which may be a result of altered EC signaling. The increase in
leukocyte numbers may originate from extendedWBC half-life and
the potentiated hematopoiesis of LSK cells in the bone marrow of
DKO mice. Indeed, CB2R activation in the bone marrow was shown
to stimulate stress-induced hematopoiesis by increasing the
marrow cellularity, LSK numbers, and bone marrow cell survival
[33]. Importantly, when we chronically treated mice with
SR144528 to block CB2R activation, we failed to observe any dif-
ferences in circulating WBC counts between ApoE/ and DKO
mice, demonstrating that CB2R signaling is responsible for the
observed effect.
Detectable plasma 2-AG levels and signiﬁcantly elevated 2-AG
concentrations in the aorta of DKO mice, together with decreased
Cb1r and Cb2r mRNA expression in aortae of DKO mice, suggest
systemic and local changes in EC signaling. Interestingly, we
observed elevatedmRNA expression ofMcp-1 and IL-1b in aortae of
DKO mice. This ﬁnding may be attributed to the reduced Cb2r
mRNA expression in the vascular tissue, leading to an elevated in-
ﬂammatory propensity due to reduction of anti-inﬂammatory ef-
fects of CB2R activation in the aorta.
En face and aortic valve section analyses demonstrated
increased plaque formation with reduced lipid content in DKO
compared to ApoE/ mice. Macrophage-derived foam cell for-
mation is considered to be a hallmark of atherosclerosis due to
subintimal macrophage accumulation and removal of modiﬁed li-
poprotein particles in an uncontrolled manner. Intraplaque
macrophage amount and intracellular TG and cholesterol concen-
trations were reduced in DKO mice. Reduced Cd36 mRNA expres-
sion and unchanged cholesterol efﬂux in DKO macrophages
indicate that decreased lipoprotein uptake rather than increased
lipid efﬂux is likely responsible for reduced foam cell formation of
DKO macrophages. In line with our data, CB2R activation in human
macrophages leads to downregulation of CD36, causing reduced
foam cell formation [34]. This effect is only in part attributable to
CB2R activation, since co-treatment with SR144528 normalizes TC
but not TG concentrations in DKO macrophages. Changes inFig. 7. CB2R antagonism reverses plaque phenotype in DKO mice. (A) Absolute WBCs aft
measurements, (C) Oil red O (ORO)-stained lipids (magniﬁcation: 5), (D) MoMa-2 im
Trichrome-stained collagen (blue) (magniﬁcation: 5), and (F) necrotic core per plaque are
and 3 aortic valve sections in the area of maximal plaque size for ORO, MoMa-2, Trichromintracellular lipid homeostasis also modulate functions of macro-
phages as important members of the innate immunity. Macrophage
FC accumulation triggers macrophage apoptosis [35], which in turn
affects atherosclerosis progression, leading to necrotic core for-
mation and reduction in efﬁcient removal of cellular debris [36].
Apoptosis, however, seems to be unaltered between ApoE/ and
DKO mice. (i) In thioglycolate-elicited DKO and ApoE/ macro-
phages, we observed comparable annexin V/PI staining after in vitro
loading with VLDL or acLDL, indicating comparable levels of
apoptosis and necrosis. (ii) Caspase-3 immunohistochemistry of
aortic valve sections revealed unaltered apoptosis in vivo. (iii)
Caspase-3 western blotting of aortae conﬁrmed the results. Beside
reduced foam cell formation, macrophage phenotype and functions
of DKO macrophages are unaltered, as evidenced by comparable
M1/M2 polarization, integrin expression, and phagocytic activity to
ApoE/ cells. DKO macrophages exposed to acLDL, however, have
reducedmRNA expression of IL-6 and increased expression of IL-10,
indicating an M2-like phenotype.
An important process in plaque pathogenesis is the formation of
a ﬁbrous cap, which protects the necrotic core from rupture and
stabilizes the lesion. Vulnerable plaques are characterized by
decreasing amounts of ﬁbrous cap collagen, increase in foam cell
formation, and build-up of the necrotic core (reviewed in [37,38]). A
thinning ﬁbrous cap decreases lesion stability, rendering athero-
sclerotic plaques susceptible to rupture and thrombus formation
[39]. Thus, reducing the ratio of collagen to necrotic core is an in-
dicator of decreased plaque stability [31]. Destabilization of plaques
due to neovessel formation was absent in both ApoE/ and DKO
mice. Of note, the necrotic core area, which contributes to inﬂam-
mation, proteolytic plaque breakdown, and physical stress on the
ﬁbrous cap [39], was reduced in plaques of DKO mice. Major de-
terminants for the amount of plaque collagen content and thus
plaque stability are collagen production (caused by inﬁltrating
smooth muscle cells) and degradation (mediated by neutrophil-
produced matrix metalloproteinases). Importantly, we found
markedly increased collagen content in lesions of DKO mice, with a
relative collagen amount comprising almost 40% of the athero-
sclerotic plaque. Comparable mRNA expression levels of Mmp-2
and -9 together with unchanged gelatinolytic capacities of (pro-)
MMP-2 and -9 from DKO neutrophil conditioned media argue
against changes in production of MMPs. Increased mRNA expres-
sion of aortic Timp-1 and Timp-2 may be a contributing factor for
hindered matrix degradation. However, the increase in collagen
plaque content of DKO mice is most likely attributable to the
increased abundance of smooth muscle cells, indicating either
increased migration of smooth muscle cells from the media into
subintimal areas or prolonged survival within the lesions. Impor-
tantly, all changes in DKO plaque phenotype were completely
reversed by chronic CB2R antagonism with SR144528, indicating
that the observed effects are due to potentiated EC signaling on
CB2R expressing cells. Although CB2R antagonism reduced DKO
plaque size to the levels found in ApoE/ mice, the lesions were
rendered more unstable with as little as 24% of total lesion size
being attributed to collagen.
It has previously been shown that chronic administration of low
doses of THC reduces plaque size [15]. However, little is known
about plaque stability and collagen content in this setting. We
argue to consider these data with caution since (i) THC is only a
partial agonist on CB2R even capable to antagonize the receptor
activation by agonists [40], (ii) administration of the drug can leader three weeks of SR144528 treatment as means (n ¼ 6) þ SD. (B) Total lesion size
munohistochemically-stained macrophages (red) (magniﬁcation: 5), (E) Masson's
a. Data represent mean values of 15 aortic valve sections for lesion size measurements
e, and necrotic core for each mouse. Data represent means (n ¼ 6) þ SD.
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ment of tolerance, and (iii) THC is capable of mediating the effects
distinct of the ones mediated by endogenous CB2R ligands
(reviewed in [41,42]). Interestingly, recent work by Steffens and
colleagues reported an opposite plaque phenotype to our DKOmice
in ApoE/FAAH/ mice [43]. FAAH efﬁciently degrades anan-
damide, the secondmolecule identiﬁed as potential EC. The authors
found reduced plaque size with comparable amount of macro-
phages and decreased plaque stability in ApoE/FAAH/
compared to ApoE/ mice. Surprisingly, elevation in plasma
anandamide concentrations in ApoE/FAAH/ mice was
accompanied by a reduction in 2-AG concentrations [43]. It is
therefore tempting to speculate that the plaque phenotype in
ApoE/FAAH/ mice may be an indirect consequence of
decreased 2-AG levels and blunted 2-AG-mediated CB2R signaling
instead of increased anandamide concentrations per se, since (i)
tissue 2-AG levels are by far more abundant than anandamide with
nanomolar versus picomolar concentrations (reviewed in [41]), (ii)
2-AG is a full whereas anandamide is a partial CBR agonist, which is
also capable to attenuate the effectiveness of 2-AG to activate CB2R
[6], and (iii) structureeactivity relationship studies suggested that
2-AG rather than anandamide is the true natural ligand for both
CB1R and CB2R [44,45]. Thus, it may be plausible that MGL and 2-
AG are the key regulators of EC homeostasis in atherosclerosis,
whereas FAAH and anandamide may act indirectly, mediating its
effects on atherogenesis via modulations in 2-AG signaling.
In summary, our data provide evidence that genetic ablation of
MGL causes alterations in EC signaling, thereby indirectly affecting
atherogenesis. Despite elevated 2-AG concentrations, CB2R-
mediated signaling remains fully functional, arguing against CB2R
desensitization. We conclude that lack of MGL modulates EC
signaling in CB2R-expressing cells and inﬂuences (patho)physio-
logical processes, which concomitantly affect the pathogenesis of
atherosclerosis. Selective CB2R activation within atherosclerotic
plaques has already been suggested to represent a promising
strategy for reducing atherosclerotic inﬂammation and related
plaque vulnerability [46]. Chronic MGL inhibition may be a novel
therapeutic intervention in atherosclerosis treatment, leading to
formation of less vulnerable atherosclerotic plaques.
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